DDInter1407 DDInter1435
Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2a. Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Peginterferon alfa-2a {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etanercept
Peginterferon alfa-2a {u} may lead to a major life threatening interaction when taken with {v} Samarium (153Sm) lexidronam
Peginterferon alfa-2a may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Etanercept
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam